OTCMKTS:NWPHF Newron Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Newron Pharmaceuticals SpA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.55 0.00 (0.00 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$2.55Now: $2.55▼$2.5550-Day Range$1.81MA: $2.34▼$2.5552-Week Range$1.80Now: $2.55▼$8.90VolumeN/AAverage Volume980 shsMarket Capitalization$45.52 millionP/E RatioN/ADividend YieldN/ABeta0.39 ProfileChartCompetitorsHeadlinesShort InterestSocial Media Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of safinamide in Japan and Asian territories. The company was founded in 1998 and is headquartered in Bresso, Italy.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Newron Pharmaceuticals. Previous Next 2.1 Community Rank Outperform VotesNewron Pharmaceuticals has received 82 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNewron Pharmaceuticals has received 109 “underperform” votes. (Add your “underperform” vote.)Community SentimentNewron Pharmaceuticals has received 57.07% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Newron Pharmaceuticals and other stocks. Vote “Outperform” if you believe NWPHF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NWPHF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNewron Pharmaceuticals does not currently pay a dividend.Dividend GrowthNewron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Newron Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Newron Pharmaceuticals are expected to decrease in the coming year, from ($0.88) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Newron Pharmaceuticals is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Newron Pharmaceuticals is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewron Pharmaceuticals has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.42 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NWPHF Previous Symbol CUSIPN/A CIKN/A Webwww.newron.com Phone39026103461Debt Debt-to-Equity Ratio0.46 Current Ratio10.72 Quick Ratio10.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.88 million Price / Sales5.78 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book1.10Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees24 Outstanding Shares17,850,000Market Cap$45.52 million Next Earnings DateN/A OptionableNot Optionable $2.55 0.00 (0.00 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NWPHF News and Ratings via Email Sign-up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter. Newron Pharmaceuticals (OTCMKTS:NWPHF) Frequently Asked Questions How has Newron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Newron Pharmaceuticals' stock was trading at $7.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NWPHF shares have decreased by 66.0% and is now trading at $2.55. View which stocks have been most impacted by COVID-19. Are investors shorting Newron Pharmaceuticals? Newron Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 100 shares, a drop of 90.0% from the August 15th total of 1,000 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 1.0 days. View Newron Pharmaceuticals' Short Interest. Who are some of Newron Pharmaceuticals' key competitors? Some companies that are related to Newron Pharmaceuticals include Chimerix (CMRX), Abeona Therapeutics (ABEO), Lexicon Pharmaceuticals (LXRX), GlycoMimetics (GLYC), Axovant Gene Therapies (AXGT), Aytu Bioscience (AYTU), Ampio Pharmaceuticals (AMPE), TAIWAN LIPOSOME/S (TLC), Aptinyx (APTX), Galectin Therapeutics (GALT), AVEO Pharmaceuticals (AVEO), Harrow Health (HROW), ContraFect (CFRX), NuCana (NCNA) and Pivot Pharmaceuticals (PVOTF). View all competitors. Who are Newron Pharmaceuticals' key executives? Newron Pharmaceuticals' management team includes the following people: Mr. Stefan Weber, CEO & Exec. Director (Age 54)Mr. Roberto Galli, VP of Fin.Mr. Marco Caremi, Exec. VP of Bus. Devel. (Age 62)Dr. Ravi Anand, Chief Medical Officer (Age 62)Mr. Dennis Dionne, VP of Commercial Affairs (Age 69) What is Newron Pharmaceuticals' stock symbol? Newron Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NWPHF." How do I buy shares of Newron Pharmaceuticals? Shares of NWPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Newron Pharmaceuticals' stock price today? One share of NWPHF stock can currently be purchased for approximately $2.55. How big of a company is Newron Pharmaceuticals? Newron Pharmaceuticals has a market capitalization of $45.52 million and generates $7.88 million in revenue each year. The company earns $-22,630,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Newron Pharmaceuticals employs 24 workers across the globe. What is Newron Pharmaceuticals' official website? The official website for Newron Pharmaceuticals is www.newron.com. How can I contact Newron Pharmaceuticals? Newron Pharmaceuticals' mailing address is via Antonio Meucci 3 Milan, Bresso L6, 20091. The company can be reached via phone at 39026103461 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
